Video

Dr. Raje on Unmet Needs with CAR T-Cell Therapy in Myeloma

Noopur Raje, MD, discusses unmet needs with CAR T-cell therapy in multiple myeloma.

Noopur Raje, MD, director, Center for Multiple Myeloma, Massachusetts General Hospital, discusses unmet needs with CAR T-cell therapy in multiple myeloma.

Access remains the most prevalent unmet need regarding CAR T-cell therapy, Raje says. Since CAR T-cell therapy is currently approved only for patients with late-stage relapsed or refractory multiple myeloma, those patients must wait and sometimes cannot receive the products in time, Raje says. Improving access for these patients is a vital concern, and moving CAR T-cell therapy into earlier stages of treatment could help improve access and expand the number of patients who could receive treatment, Raje adds.

Ciltacabtagene autoleucel (cilta-cel; Carvykti) and idecabtagene vicleucel (ide-cel; Abecma) are currently being investigated in the up-front setting in clinical trials, Raje continues. Once the indication is received in earlier stages of myeloma, bridging therapies will help more patients receive CAR T-cell therapy, Raje concludes.

Related Videos
Daniel DeAngelo, MD, PhD
Marc J. Braunstein, MD, PhD, associate professor, Department of Medicine, co-director, Hematology-Oncology System, New York University (NYU) Grossman Long Island School of Medicine
Douglas W. Sborov, MD, MS, associate professor, Department of Internal Medicine—Division of Hematology and Hematologic Malignancies; director, Hematology Disease Center and Plasma Cell Dyscrasias Program, the University of Utah Huntsman Cancer Institute
Bradley C. Carthon, MD, PhD
David C. Fisher, MD
Alan Tan, MD
Binod Dhakal, MD
Sheldon M. Feldman, MD
Yair Lotan, MD, UT Southwestern Medical Center
Alan Tan, MD, Vanderbilt-Ingram Cancer Center